PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

To determine the efficacy of PT320 on L-DOPA-induced dyskinetic behaviors, and neurochemistry in a progressive Parkinson’s disease (PD) MitoPark mouse model. To investigate the effects of PT320 on the manifestation of dyskinesia in L-DOPA-primed mice, a clinically translatable biweekly PT320 dose wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Tung-Tai, Chen, Yuan-Hao, Wang, Vicki, Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Greig, Nigel H., Jung, Jin, Choi, Ho-II, Olson, Lars, Hoffer, Barry J., Tseng, Kuan-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002999/
https://www.ncbi.nlm.nih.gov/pubmed/36902115
http://dx.doi.org/10.3390/ijms24054687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002999/
https://www.ncbi.nlm.nih.gov/pubmed/36902115
http://dx.doi.org/10.3390/ijms24054687

Ejemplares similares